Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
Ferring launches new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive...